GLP-1s and muscle — how much lean mass you actually lose.

The market has two settings on this question: silence, from the people selling the drugs, and sirens, from the people selling you the fix. The trial data sits in the middle, and it is specific enough to be useful. Here is what the DXA substudies actually measured.

Two markets, one missing answer

Ask what GLP-1s do to muscle and the answer you get depends entirely on who profits from your reaction. The pharmaceutical marketing around semaglutide and tirzepatide barely mentions body composition — the story is pounds and A1C. Meanwhile an entire secondary economy of supplements, coaching programs, and gray-market compounds has built its pitch on the word sarcopenia, wielding the scariest available number as if it described pure muscle evaporating. One side needs you calm. The other needs you frightened. Neither starts with the substudies.

The substudies exist, they used DXA — dual-energy X-ray absorptiometry, the standard body-composition scan — and their numbers are specific. That is where we start.

What the trials measured

STEP 1 was semaglutide's pivotal obesity trial: 68 weeks, 2.4 mg weekly, mean weight reduction approximately 14.9%, published in the New England Journal of Medicine in 2021. Within it, a DXA substudy scanned a subset of participants before and after — and found that roughly 39% of total weight lost was lean body mass. SURMOUNT-1 was tirzepatide's counterpart: 72 weeks, with the 15 mg arm averaging approximately 20.9% weight reduction, published in 2022. Its body-composition subanalysis put the lean share of weight lost at roughly a quarter.

Resist the urge to read that table as a verdict that tirzepatide "spares muscle" and semaglutide does not. These are substudies of different trials, on subsets of participants, with different populations and durations — the same cross-trial caution we apply everywhere else on this site. What the two numbers establish together is the honest range: when these drugs take a large amount of weight off, somewhere between a quarter and two-fifths of it, by DXA, is not fat.

What "lean mass" actually includes

Here is where the scare copy cheats. DXA divides you into three compartments — fat, bone mineral, and everything else. That third compartment, "lean mass," is skeletal muscle plus water, organ tissue, skin, and connective tissue. When total body mass drops fast, some of the lean-compartment decline is water and the general shrinkage of a smaller body — organs and support tissue scale down with the frame they serve. Skeletal muscle is only part of the lean number, which means "39% of the loss was lean mass" and "39% of the loss was muscle" are different sentences, and only the first one is supported.

That correction cuts the alarm down — but not to zero. Muscle is in there, the decline is real, and pretending the water content of the lean compartment makes the whole number an artifact is the calm-side version of the same cheat.

Why it matters — three reasons, ranked

Regain quality. This is the one the market talks about least and the data supports most directly. Weight regain after stopping these drugs is common — and regain arrives disproportionately as fat. A person who loses 25% of body weight at a 39% lean share, stops, and regains half of it can end the round-trip lighter but with a worse body composition than they started with. The lean tissue lost on the way down is not automatically restored on the way back up.

Function. Strength and mobility ride on muscle, and the relationship gets unforgiving with age. For a 35-year-old with substantial fat mass, a few kilograms of lean loss is recoverable noise. For a 68-year-old, the same loss can be the difference between climbing stairs comfortably and not.

Metabolic rate. Lean tissue is the metabolically expensive part of you. Lose it and resting energy expenditure drifts down — modestly per kilogram, but in the direction that makes maintenance harder. This is the most commonly cited reason and the least dramatic in magnitude; we rank it third on purpose.

The context the sirens leave out

Lean mass loss is not a GLP-1 invention. It is a property of losing weight fast. Caloric-restriction diets take lean tissue. Very-low-calorie protocols take more. Bariatric surgery — the previous benchmark for rapid, large-scale loss — takes a substantial lean share too. The body in a deep deficit does not politely burn only fat; it never has.

What the drugs genuinely changed is distribution and scale. Surgical-magnitude weight loss used to happen to a small population, screened and followed by clinical teams. GLP-1s deliver it to millions — most of whom received a prescription, not a training program, and many of whom are eating well under their protein needs precisely because the drug has deleted their appetite. The compound-specific effect and the context-specific effect point the same direction, and the context is the part you control.

The two counterweights that actually have evidence

The fix-selling economy offers you dozens of answers. The exercise-science literature offers two, and neither is for sale in a dropper bottle.

Resistance training. The finding that lifting preserves lean mass during a caloric deficit is one of the most consistently replicated results in the field — across diet studies, across populations, across decades. It does not require heroic volume; it requires progressive load, done regularly, through the loss phase. This is the single highest-leverage variable a person losing weight on an incretin controls.

Protein. Appetite suppression suppresses protein intake along with everything else, which is exactly the wrong nutrient to lose. Intakes around 1.6-2.2 g per kg per day are the commonly cited targets in the sports-nutrition literature for preserving lean mass in a deficit — a range that a person eating 40% fewer total calories will not hit by accident. Protein has to be planned first, not left to whatever appetite remains.

Neither counterweight is exotic, which is precisely why the market underweights them. There is no margin in telling you to lift and eat protein. There is enormous margin in telling you the muscle is melting and the answer costs $89 a month.

Who should care most

Two groups sit closest to the edge. Older adults start nearer to functional thresholds, rebuild muscle more slowly, and are the population where the word sarcopenia stops being marketing and starts being medicine — for them, the resistance-training and protein counterweights are not optimization, they are the core of doing this safely. Already-lean users — people reaching for these drugs to drop a modest amount — are the second group, because weight lost from an already-lean body draws proportionally more from lean tissue. The person with the least fat to give has the most muscle at stake, and that is exactly the user profile the gray market has been growing fastest.

The industry knows — and is building the sequel

Nothing confirms the lean-mass question like the drug industry's own pipeline. Muscle-preservation compounds designed to pair with incretin therapy are in active clinical development across several companies — the explicit bet being that the next generation of weight-loss treatment is a combination: one drug for the fat, one to hold the muscle. None of these agents is approved for that use today, and we are not going to launder pipeline press releases into trial results by naming candidates here. The gray market, predictably, is already selling its own versions of that story, well ahead of the evidence. When those programs publish, we will cover the data. Until then, the two counterweights above are what exists — and how this class's broader side-effect profile fits around them is covered in our side-effects fundamentals.

One more note on where this collides with the research-compound economy: the muscle-loss numbers above come from pharmaceutical-grade drugs in supervised trials. The gray-market versions of these molecules — covered across our compound index and in our COA guide — add quality variance on top of everything this article describes. Questions about how research dosing is even discussed belong in our dosing fundamentals, not here.

FAQ

References & further reading

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity [STEP 1]. N Engl J Med. 2021;384:989-1002 — including the DXA body-composition substudy.
2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity [SURMOUNT-1]. N Engl J Med. 2022;387:205-216 — with the body-composition subanalysis.
3. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514-526.
4. Sports-nutrition literature on protein targets of 1.6-2.2 g/kg/day for lean-mass preservation in a caloric deficit — commonly cited consensus range.
5. Inside Your Peptides, Retatrutide: What the Data Actually Shows — the evidence review
6. Inside Your Peptides, Side Effects Fundamentals — the incretin class in practice

disclosure: inside your peptides may earn referral fees from vendor links elsewhere on this site — this article carries none. grades and rankings follow the published criteria in our editorial policy — never referral terms. research + education only · not medical advice.